The following serious concerns, as reported in the BMJ, 22 July 2023, hardly seemed to appear in the worldwide trailblazing headlines of the latest anti-amyloid drug. I wonder why?
“The hyperbole in the media and scientific response is unjustified and cruel to patients”
